ADC Franchise page edits 12 2017
The investigational Antibody Drug Conjugate (ADC) Franchise of the Daiichi Sankyo Cancer Enterprise is built around our proprietary technology, which is being researched across multiple types of cancer.
Daiichi Sankyo Proprietary ADC Technology
ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy directly to cancer cells. An ADC consists of three components:
1) a monoclonal antibody
2) a cytotoxic chemotherapy payload
3) a linker that joins the two together
Using expertise in both protein engineering and medicinal chemistry, our team of exceptional scientists has methodically designed proprietary Daiichi Sankyo ADC technology.
The cornerstone of our ADC Franchise is a proprietary payload and linker-payload technology, which consists of:
- Payload: DXd, a novel topoisomerase I inhibitor
- Linker: A proprietary tetrapeptide-based linker that joins the antibody and payload together, and is designed to be broken down by lysosomal enzymes such as cathepsins, which are highly expressed in tumor cells
Our linker-payload combination allows for a Drug-Antibody Ratio (DAR) of up to about 8, meaning up to eight molecules of DXd can be conjugated per antibody.
Our ADC Franchise currently consists of six novel ADCs, including DS-8201 in phase 2 clinical development, U3-1402 in phase 1/2 clinical development, DS-1062 in phase 1 development, as well as DS-7300, DS-6157 and DS-6000 in preclinical development.
We are open to partnership opportunities with external companies to combine our linker-payload technology with other monoclonal antibodies as well as collaborations with other compounds to study in combination with our ADC assets.
These are investigational agents and have not been approved by the FDA or any other worldwide regulatory agency as a treatment for any indication. Safety and efficacy have not been established.
Antibody Drug Conjugate (ADC) Franchise
DS-8201 is the lead product in the ADC Franchise of the Daiichi Sankyo Cancer Enterprise. DS-8201 is an investigational ADC currently in phase 2 development for HER2-positive unresectable and/or metastatic breast cancer resistant or refractory to ado-trastuzumab emtansine (T-DM1) (DESTINY-Breast01), phase 2 development for HER2-positive advanced gastric cancer resistant or refractory to trastuzumab (DESTINY-Gastric01), phase 2 development for HER2-positive advanced colorectal cancer and phase 1 development for other HER2-expressing advanced/unresectable or metastatic solid tumors.
DS-8201 has been granted Breakthrough Therapy designation for the treatment of patients with HER2-positive, locally advanced or metastatic breast cancer who have been treated with trastuzumab and pertuzumab and have disease progression after ado-trastuzumab emtansine (T-DM1), and Fast Track designation for the treatment of HER2-positive unresectable and/or metastatic breast cancer in patients who have progressed after prior treatment with HER2-targeted therapies including T-DM1 by the U.S. Food and Drug Administration (FDA).
U3-1402 is an investigational and potential first-in-class HER3-targeting ADC currently in phase 1/2 development for HER3-expressing metastatic or unresectable breast cancer and phase 1 development for metastatic or unresectable epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).
DS-1062 is an investigational TROP2-targeting ADC currently in phase 1 development for unresectable advanced non-small cell lung cancer (NSCLC).